Ovarian Cancer News & Features

CNN's Amanpour Being Treated for Ovarian Cancer CNN's Amanpour Being Treated for Ovarian Cancer June 14, 2021Christiane Amanpour, the chief international anchor for CNN, announced Monday at the start of her daily TV program that she’s been diagnosed with ovarian cancer."I've had successful major surgery to remove it, and I'm now undergoing several months of chemotherapy for the very best possible long-term prognosis, and I'm confident," Amanpour said, according to a story on CNN’s website.Amanpour, 63, noted that ovarian cancer affects “millions of women around the world.” “I’m telling you this in the interest of transparency, but in

The U.S. Supreme court said Tuesday that it won't hear Johnson & Johnson's appeal over a $2 billion ruling in favor of women who said they developed ovarian cancer from using the company's talc products.

Here’s what people with ovarian cancer want you to know about this condition.

Learning to live with ovarian cancer can feel overwhelming. But there are ways to ease the transition.

A huge British trial turned out negative: annual screening of healthy women for ovarian cancer did not reduce deaths from this aggressive cancer.

A new blood test claims to find up to 50 different cancers from single blood draw; it may be used to along with other cancer screening tests.

Here’s what two doctors who treat gynecologic cancers want you to know about spotting ovarian cancer as early as possible.

When used under a doctor’s supervision, complementary therapies can make it easier to get through treatment for ovarian cancer. Here’s what you should know.

A recent study suggests that "maintenance therapy" with a targeted cancer drug may add years to some patients' lives.

Previous studies suggested that women who used this assisted reproductive technologies (ART) such as IVF to get pregnant may be at risk for ovarian cancer and non-malignant borderline tumors

Survival of patients with advanced ovarian cancer continues to increase, despite concerns that increased use of neoadjuvant chemotherapy (NAC) could have a negative impact on outcomes.

At only 2 years of age, McKenna Xydias is a cancer survivor.

or the study, the investigators analyzed data from the U.S. National Cancer Database. They compared nearly 36,000 women who were diagnosed and treated between 2004 and 2009, with more than 37,000 women diagnosed and treated between 2011 and 2014.

After adjusting for such factors as age and whether women had ever given birth, any use of birth control pills was associated with a 46% lower risk of death within a year of an ovarian cancer diagnosis, the study found.

Johnson & Johnson is being investigated by the U.S. Justice Department and the U.S. Securities and Exchange Commission over possible asbestos contamination of the company's baby powder and other talc-based products.

Researchers say that women who reported recent, regular use of low-dose aspirin (100 milligrams or less) had a 23 percent lower risk of developing ovarian cancer than those who did not regularly take aspirin.

One low-dose aspirin -- the type many older women already take to help their hearts -- was tied to a 10 percent reduction in developing ovarian cancer and as much as a 30 percent improvement in survival for ovarian cancer patients, two new studies have found.

A jury says Johnson & Johnson must pay $4.62 billion to 22 women who allege they developed ovarian cancer after using the company's Baby Powder and Shower to Shower brand talcum powder as part of their daily feminine hygiene routine.

However, there is a slight risk that the ovarian tissue may contain cancer cells, putting a woman at risk for the return of her cancer.

One study found that a new targeted "immunotherapy" to treat ovarian cancer that has come back looked promising in a small, early trial.

The researchers behind the new study developed a testing regimen called PapSEEK to see if additional samples collected during a pelvic exam could be used to detect endometrial or ovarian cancer.

Screening not only didn’t prevent any deaths, it also led to harm, the panel said.

According to the study from the U.S. National Cancer Institute, these trends were also observed for endometrial cancer as well.

Award in Missouri case set aside upon appeal. Does not affect larger California award in similar suit.

Verdict was fourth against Johnson & Johnson